Opthea Ltd
Opthea Ltd (OPTEY): 2 pipeline candidates · 1 upcoming catalyst · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
N/A
D/E -1.28 · 0% dilution
Lead: Phase 3
2 candidates
1 upcoming, next in ~36d
N/A
A transparent, data-derived signal for Opthea Ltdacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.2M
Cash
$48.4M
Quarterly Burn
—
Runway
—
Revenue
—
Cash Runway vs Catalysts
Upcoming catalyst timeline.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| 2.0 mg opt-302 | Phase 3 |
| opt-302 | Phase 3 |
Upcoming Catalysts (1)
Frequently asked questions
How many drug candidates are in Opthea Ltd's pipeline?
Opthea Ltd (OPTEY) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Opthea Ltd's lead drug candidate?
Opthea Ltd's most advanced tracked candidate is 2.0 mg opt-302 (Phase 3) for Neovascular Age-related Macular Degeneration.
What is Opthea Ltd's next catalyst?
Opthea Ltd's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: AKTEN" — expected July 24, 2026.
What is Opthea Ltd's market capitalization?
Opthea Ltd's market capitalization is approximately $3.2M.
Who is the CEO of Opthea Ltd?
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. is the chief executive officer of Opthea Ltd (OPTEY).
Get the full picture on Opthea Ltd
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.